Schrödinger believes that the true measure of its drug discovery software’s success lies in the contribution it makes to actual drug discovery programs. As such, in the past several years Schrödinger has engaged in a wide range of drug discovery collaborations.
 
The Drug Discovery Applications Group (DDAG), a multi-disciplinary team within Schrödinger, comprises medicinal and computational chemists most of whom joined Schrödinger from the pharmaceutical industry after years of celebrated careers replete with patents and successful drug discovery programs. Working alongside partners that range from leading academic groups and small biotechs to major pharmaceutical companies in the US and Europe, DDAG has tackled lead discovery, hit-to-lead, and lead optimization projects. A variety of drug targets have been addressed, including kinases, membrane proteins, enzymes, anti-viral, and anti-bacterial targets, as well as protein-protein interactions.  To date Schrödinger has participated in approximately 30 collaborations, many of which have achieved success-based milestones, and some of which have now progressed to the identification of development and clinical candidates.

If you would like to learn more about our drug discovery collaborations, please contact us at ddag_info@schrodinger.com.